Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
BCR and leukemia are reported together in 17 articles.
Gene
BCR
- HGNC
- HGNC:1014
23articles
23mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Leukemia
652articles
652mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
17 records shown · first 60The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.
PMID 41263163 | DOI 10.1080/10428194.2025.2590596 · Leukemia & lymphoma · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Genomic profiling reveals frequent CRLF2 rearrangements, JAK-STAT pathway mutations, and high-risk subtypes such as BCR::ABL1-like disease.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CRLF2 | “Genomic profiling reveals frequent CRLF2 rearrangements, JAK-STAT pathway mutations, and high-risk subtypes such as BCR::ABL1-like disease.” | 0.98 | hgnc_dict_v1 |
| phenotype | Down syndrome | “The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.” | 0.98 | phenotype_alias_lexicon_v2 |
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.
PMID 41963641 | DOI 10.1038/s41409-026-02862-9 · Bone marrow transplantation · 2026 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Most centres conduct monthly BCR::ABL1 transcript monitoring during the first three months post-transplant, transitioning to quarterly assessments upon achieving a deep molecular response.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “Twenty-three centres (59%) responded, providing clinical perspectives into pre-transplant chemotherapy regimens, TKI use, ABL1 kinase domain mutation analysis, post-transplant monitoring, and their practice regarding sequencing/ integration of TKIs with donor lymphocyte infusions (DLI).” | 0.98 | hgnc_dict_v1 |
Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.
PMID 38831894 | PMCID PMC11145380 | DOI 10.1016/j.sjbs.2024.104027 · Saudi journal of biological sciences · 2024 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “The molecular analysis results unveiled mutations in specific genes (FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS) targeted by nine microRNAs.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | CD99 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
| gene | CD34 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16.
PMID 39215452 | PMCID PMC11373876 | DOI 10.12659/AJCR.944641 · The American journal of case reports · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome, which results from the fusion of the translocation of the ABL1 gene from chromosome 9 to the BCR gene located in chromosome 22, forming the BCR-ABL gene on chromosome number 22, which accounts for approximately 95% of CML cases.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome, which results from the fusion of the translocation of the ABL1 gene from chromosome 9 to the BCR gene located in chromosome 22, forming the BCR-ABL gene on chromosome number 22, which accounts for approximately 95% of CML cases.” | 0.98 | hgnc_dict_v1 |
A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene.
PMID 36864712 | PMCID PMC9989977 | DOI 10.12659/AJCR.938488 · The American journal of case reports · 2023 · 8 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “BACKGROUND Breakpoint cluster region (BCR)-Abelson murine leukemia (ABL1) and Janus Kinase-2 (JAK2) mutations have been thought to be mutually exclusive in myeloproliferative neoplasms (MNPs), but recent data suggest that they can occur together.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | JAK2 | “A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene.” | 0.98 | hgnc_dict_v1 |
| gene | ABL1 | “BACKGROUND Breakpoint cluster region (BCR)-Abelson murine leukemia (ABL1) and Janus Kinase-2 (JAK2) mutations have been thought to be mutually exclusive in myeloproliferative neoplasms (MNPs), but recent data suggest that they can occur together.” | 0.98 | hgnc_dict_v1 |
Prevalence of the BCR/ABL fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.
PMID 36915720 | PMCID PMC10006767 · American journal of translational research · 2023 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Prevalence of the BCR/ABL fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Prevalence of the BCR/ABL fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD34 | “Dendritic cell (DC) vaccines are promising for immunotherapy, and their production using CD34+ hematopoietic stem cells (HPSCs) from patients with chronic myelogenous leukemia (CML) and healthy donors is well established.” | 0.98 | hgnc_dict_v1 |
| gene | CD80 | “DCs from CD34-Lin- and CD34+Lin- HPSCs expressed comparable surface markers (CD80, CD83, CD86, HLA-DR, CD40, and CD54).” | 0.98 | hgnc_dict_v1 |
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
PMID 35421941 | PMCID PMC9008925 | DOI 10.1186/s12885-022-09481-9 · BMC cancer · 2022 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “BACKGROUND: There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “BACKGROUND: There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations.” | 0.98 | hgnc_dict_v1 |
| gene | DAPK1 | “RESULTS: We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents.” | 0.98 | hgnc_dict_v1 |
Saudi Arabian CML patient with a novel four-way translocation at t(9;22;5;2)(q34;q11.2;p13;q44).
PMID 35543309 | PMCID PMC9184659 | DOI 10.1002/mgg3.1865 · Molecular genetics & genomic medicine · 2022 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “BACKGROUND: The vast majority of chronic myeloid leukemia (CML) patients have a single translocation t(9;22)(q34;q11), BCR/ABL1 fusion genes, which is regarded as the hallmark of CML.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “BACKGROUND: The vast majority of chronic myeloid leukemia (CML) patients have a single translocation t(9;22)(q34;q11), BCR/ABL1 fusion genes, which is regarded as the hallmark of CML.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “BACKGROUND: The vast majority of chronic myeloid leukemia (CML) patients have a single translocation t(9;22)(q34;q11), BCR/ABL1 fusion genes, which is regarded as the hallmark of CML.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Saudi Arabian CML patient with a novel four-way translocation at t(9;22;5;2)(q34;q11.2;p13;q44). METHODS: This case report is based on a 40-year-old Saudi Arabian male patient, diagnosed with CML in lymphoid blast crisis, and observed to have a four-way 46 XY, t(9;22;5;2)(q34;q11.2;p13;q44) translocation.” | 0.95 | saudi_context_rules_v1 |
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
PMID 28971501 | DOI 10.1002/ajh.24926 · American journal of hematology · 2018 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “The Ph chromosome, results from a reciprocal translocation of the ABL1 kinase gene on chromosome 9 to the breakpoint cluster region (BCR) gene on chromosome 22.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “The Ph chromosome, results from a reciprocal translocation of the ABL1 kinase gene on chromosome 9 to the breakpoint cluster region (BCR) gene on chromosome 22.” | 0.98 | hgnc_dict_v1 |
A rare case of three-way complex variant translocation in chronic myeloid leukemia t(6;9;22)(p21;q34;q11): A case report.
PMID 29085635 | PMCID PMC5649580 | DOI 10.3892/br.2017.967 · Biomedical reports · 2017 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “A FISH test was carried out to recognize the BCR/ABL gene fusion, and a cytogenetic analysis was performed.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “A rare case of three-way complex variant translocation in chronic myeloid leukemia t(6;9;22)(p21;q34;q11): A case report.” | 0.98 | phenotype_alias_lexicon_v2 |
A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report.
PMID 27602125 | PMCID PMC4998593 | DOI 10.3892/ol.2016.4821 · Oncology letters · 2016 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Imatinib mesylate is the first line breakpoint cluster region-Abelson gene (BCR/ABL)-targeted oral therapy for CML, and may produce a complete response in 70-80% of CML patients in the chronic phase.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report.” | 0.98 | phenotype_alias_lexicon_v2 |
Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient.
PMID 26622740 | PMCID PMC4533745 | DOI 10.3892/ol.2015.3495 · Oncology letters · 2015 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Results of hematological analysis showed the induced values of white blood cells (168,5000/mm3) and platelets (300,000/mm3) and FISH analysis test showed that 98% cells were positive for BCR/ABL gene translocation.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient.” | 0.98 | phenotype_alias_lexicon_v2 |
A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.
PMID 24959016 | PMCID PMC4065481 | DOI 10.4103/0971-6866.132758 · Indian journal of human genetics · 2014 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “In case of CML, the classic fusions are b2a2 or b3a2, fusing exon 13 (b2) or exon 14 (b3) of BCR, respectively, to exon 2 (a2) of ABL.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.” | 0.98 | phenotype_alias_lexicon_v2 |
Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
PMID 19943786 | DOI 10.1089/gtmb.2009.0126 · Genetic testing and molecular biomarkers · 2010 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “AIM: The aim of this study was to evaluate the response and resistance of cases to chronic myeloid leukemia (CML) therapy with tyrosine kinase (TK) inhibitors (imatinib mesylate) and to search for mutations in the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) kinase domain prior to and during therapy.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia. RESULTS: There were 85 cases of CML Philadelphia-chromosome-positive patients.” | 0.95 | saudi_context_rules_v1 |
Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.
PMID 20063526 | DOI 10.1016/s1658-3876(08)50058-6 · Hematology/oncology and stem cell therapy · 2008 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.” | 0.98 | phenotype_alias_lexicon_v2 |
Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.
PMID 17496935 · Journal of the Egyptian National Cancer Institute · 2006 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD33 | “PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients. PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.” | 0.95 | saudi_context_rules_v1 |
Molecular hematology. Qualitative to quantitative techniques.
PMID 16228048 · Saudi medical journal · 2005 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BCR | “The Section of Hematology, Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Center has shared this experience during the last 10 years with more than 6,546 samples submitted for the analysis of different gene rearrangements, fusion gene transcripts and gene mutations including Ig heavy chain gene rearrangement for B-cell malignancies, T-cell receptor gamma chain gene rearrangement for T-cell malignancies, BCR/ABL-P210 and P190 fusion gene transcripts, for chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia, PML/RARalpha fusion gene for promyelocytic leukemia, AML1/ETO for acute myeloid leukemia AML-M2 with t8;21, CBFB/MYH11 for AML M4E0 with inv 16, BCL-2 for follicular lymphoma, and BCL-1 for mantle cell lymphoma.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The Section of Hematology, Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Center has shared this experience during the last 10 years with more than 6,546 samples submitted for the analysis of different gene rearrangements, fusion gene transcripts and gene mutations including Ig heavy chain gene rearrangement for B-cell malignancies, T-cell receptor gamma chain gene rearrangement for T-cell malignancies, BCR/ABL-P210 and P190 fusion gene transcripts, for chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia, PML/RARalpha fusion gene for promyelocytic leukemia, AML1/ETO for acute myeloid leukemia AML-M2 with t8;21, CBFB/MYH11 for AML M4E0 with inv 16, BCL-2 for follicular lymphoma, and BCL-1 for mantle cell lymphoma.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PML | “The Section of Hematology, Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Center has shared this experience during the last 10 years with more than 6,546 samples submitted for the analysis of different gene rearrangements, fusion gene transcripts and gene mutations including Ig heavy chain gene rearrangement for B-cell malignancies, T-cell receptor gamma chain gene rearrangement for T-cell malignancies, BCR/ABL-P210 and P190 fusion gene transcripts, for chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia, PML/RARalpha fusion gene for promyelocytic leukemia, AML1/ETO for acute myeloid leukemia AML-M2 with t8;21, CBFB/MYH11 for AML M4E0 with inv 16, BCL-2 for follicular lymphoma, and BCL-1 for mantle cell lymphoma.” | 0.98 | hgnc_dict_v1 |
| gene | CBFB | “The Section of Hematology, Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Center has shared this experience during the last 10 years with more than 6,546 samples submitted for the analysis of different gene rearrangements, fusion gene transcripts and gene mutations including Ig heavy chain gene rearrangement for B-cell malignancies, T-cell receptor gamma chain gene rearrangement for T-cell malignancies, BCR/ABL-P210 and P190 fusion gene transcripts, for chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia, PML/RARalpha fusion gene for promyelocytic leukemia, AML1/ETO for acute myeloid leukemia AML-M2 with t8;21, CBFB/MYH11 for AML M4E0 with inv 16, BCL-2 for follicular lymphoma, and BCL-1 for mantle cell lymphoma.” | 0.98 | hgnc_dict_v1 |